Show simple item record

dc.contributor.authorFuchs, Flávio Dannipt_BR
dc.contributor.authorDiNicolantonio, James J.pt_BR
dc.date.accessioned2019-12-20T04:03:18Zpt_BR
dc.date.issued2015pt_BR
dc.identifier.issn2053-3624pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/203592pt_BR
dc.description.abstractAngiotensin receptor blockers (ARBs) are the most commonly used among blood pressure-lowering drugs worldwide, despite the absence of sound evidence of effectiveness in large and unbiased clinical trials. Metaanalyses published in recent years and reviewed here have not given support to this preference, suggesting that ARBs may be ineffective in the prevention of all cause mortality and major cardiovascular events (particularly myocardial infarction). There is evidence that ARB can be harmful for the kidney, particularly in patients with diabetes and in the elderly. It may be time to call for a moratorium on the preference for ARB in the management of hypertension and in patients with high cardiovascular risk.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofOpen heart. [London]. Vol. 2, no. 1 (2015), [4 p.]pt_BR
dc.rightsOpen Accessen
dc.subjectPré-hipertensãopt_BR
dc.subjectBloqueadores do receptor tipo 1 de angiotensina IIpt_BR
dc.subjectCardiopatiaspt_BR
dc.titleAngiotensin receptor blockers for prevention of cardiovascular disease : where does the evidence stand?pt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000996754pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record